Stockreport

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor ant [Read more]